CN1146421C - 治疗疼痛的组合物以及药物在制备所述组合物中的应用 - Google Patents

治疗疼痛的组合物以及药物在制备所述组合物中的应用 Download PDF

Info

Publication number
CN1146421C
CN1146421C CNB971949514A CN97194951A CN1146421C CN 1146421 C CN1146421 C CN 1146421C CN B971949514 A CNB971949514 A CN B971949514A CN 97194951 A CN97194951 A CN 97194951A CN 1146421 C CN1146421 C CN 1146421C
Authority
CN
China
Prior art keywords
pain
olanzapine
drug
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971949514A
Other languages
English (en)
Chinese (zh)
Other versions
CN1219877A (zh
Inventor
H��E����ũ
H·E·香农
÷
D·E·沃梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1219877A publication Critical patent/CN1219877A/zh
Application granted granted Critical
Publication of CN1146421C publication Critical patent/CN1146421C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
CNB971949514A 1996-03-25 1997-03-24 治疗疼痛的组合物以及药物在制备所述组合物中的应用 Expired - Fee Related CN1146421C (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1413096P 1996-03-25 1996-03-25
US1413296P 1996-03-25 1996-03-25
US1412996P 1996-03-25 1996-03-25
US1412896P 1996-03-25 1996-03-25
US60/014,130 1996-03-25
US60/014,129 1996-03-25
US60/014,128 1996-03-25
US60/014,132 1996-03-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA031556345A Division CN1494907A (zh) 1996-03-25 1997-03-24 治疗疼痛的药物组合物

Publications (2)

Publication Number Publication Date
CN1219877A CN1219877A (zh) 1999-06-16
CN1146421C true CN1146421C (zh) 2004-04-21

Family

ID=27486362

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB971949514A Expired - Fee Related CN1146421C (zh) 1996-03-25 1997-03-24 治疗疼痛的组合物以及药物在制备所述组合物中的应用
CNA031556345A Pending CN1494907A (zh) 1996-03-25 1997-03-24 治疗疼痛的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA031556345A Pending CN1494907A (zh) 1996-03-25 1997-03-24 治疗疼痛的药物组合物

Country Status (16)

Country Link
US (1) US5945416A (2)
EP (1) EP0921802A4 (2)
JP (1) JP2000507945A (2)
CN (2) CN1146421C (2)
AU (1) AU725556B2 (2)
BR (1) BR9708254A (2)
CA (1) CA2250187A1 (2)
CZ (1) CZ296263B6 (2)
EA (1) EA000976B1 (2)
IL (1) IL126203A (2)
NO (1) NO318035B1 (2)
NZ (1) NZ332039A (2)
PL (1) PL187926B1 (2)
UA (1) UA48219C2 (2)
WO (1) WO1997035586A1 (2)
YU (1) YU42198A (2)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
WO1999001121A1 (en) 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911049A (pt) * 1998-05-22 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de depressão resistente
IL139591A0 (en) * 1998-05-29 2002-02-10 Lilly Co Eli Combination therapy for treatment of bipolar disorders
DK1113797T3 (da) * 1998-09-15 2010-02-01 Lilly Co Eli Anvendelse af duloxetin til behandling af fibromyalgi
US6465458B1 (en) 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
CN1251758C (zh) 2000-07-21 2006-04-19 特瓦制药工业有限公司 丙戊酸和2－丙基戊烯酸酰胺的衍生物在制备治疗双极情感障碍症躁狂病药物中的用途
IL154470A0 (en) * 2000-08-17 2003-09-17 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2006505489A (ja) * 2002-02-08 2006-02-16 アボット・ラボラトリーズ 精神分裂病の治療のための併用療法
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
WO2003101492A2 (en) * 2002-05-30 2003-12-11 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
WO2004047844A1 (en) 2002-11-26 2004-06-10 Alexza Pharmaceuticals, Inc. Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
NZ540208A (en) * 2002-11-26 2007-09-28 Alexza Pharmaceuticals Inc Treatment of headache with antipsychotics delivered by inhalation
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
DE102004011392A1 (de) * 2004-01-13 2005-08-04 Grünenthal GmbH Schwache bis mittelstarke Opioide oder Kombinationen dieser Opioide mit Antidepressiva für die Behandlung von Depressionen, Angststörungen und Schmerzen
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
TWI432196B (zh) * 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
AU2006318476A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
EP3468540A4 (en) * 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7575099B2 (ja) 2018-11-07 2024-10-29 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処理のための新規な化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
DK0582368T3 (da) * 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CZ298398A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method

Also Published As

Publication number Publication date
EA199800857A1 (ru) 1999-02-25
CZ298298A3 (cs) 1999-01-13
CN1494907A (zh) 2004-05-12
PL187926B1 (pl) 2004-11-30
IL126203A (en) 2002-12-01
AU725556B2 (en) 2000-10-12
NO984431D0 (no) 1998-09-23
YU42198A (sh) 1999-09-27
BR9708254A (pt) 1999-08-03
IL126203A0 (en) 1999-05-09
NO984431L (no) 1998-11-19
PL329211A1 (en) 1999-03-15
CA2250187A1 (en) 1997-10-02
WO1997035586A1 (en) 1997-10-02
JP2000507945A (ja) 2000-06-27
NO318035B1 (no) 2005-01-24
EP0921802A1 (en) 1999-06-16
US5945416A (en) 1999-08-31
CZ296263B6 (cs) 2006-02-15
AU2543097A (en) 1997-10-17
EP0921802A4 (en) 2002-05-08
UA48219C2 (uk) 2002-08-15
NZ332039A (en) 2000-06-23
EA000976B1 (ru) 2000-08-28
CN1219877A (zh) 1999-06-16

Similar Documents

Publication Publication Date Title
CN1146421C (zh) 治疗疼痛的组合物以及药物在制备所述组合物中的应用
US6489341B1 (en) Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
TWI598098B (zh) 脂質異常症治療劑
CN1642547A (zh) 治疗中枢神经系统障碍的药物组合物和方法
CN1049336C (zh) 异恶唑衍生物在制备治疗肠应激综合征的组合物中的用途
JP2022105159A (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1917876A (zh) 方法和组合物
CN1655786A (zh) Dpp iv抑制剂和心血管化合物的组合
CN1901938A (zh) Dpp－iv抑制剂与抗肥胖药或食欲调节药的组合
CN1148188C (zh) 镇痛剂
CN1726028A (zh) 固体口服剂型药物
CN1219878A (zh) 治疗疼痛的方法
CN1106196C (zh) 奥氮平在制备用于治疗偏头痛的药物中的应用
CN1723021A (zh) 稳定的口服固体药物组合物
CN1100634A (zh) 用四氢苯并[cd]吲哚-6-甲酰胺类化合物预防呕吐和治疗性机能障碍的方法
CN1819822A (zh) 含有取代喹啉和取代二苯砜的组合物以及使用方法
TW201630902A (zh) 化合物、組合物及方法
CN1418097A (zh) 噁唑烷酮片剂的配方
CN1208349A (zh) 治疗疼痛的组合物
CN1213966A (zh) 治疗两极紊乱的方法
HK1064603A (en) Pharmaceutical composition for treatment of pain
CN1870993A (zh) 基于咪唑克生盐或其一种多晶型物的药物组合物
CN1124847C (zh) 治疗过度攻击行为的方法
TW201618776A (zh) 脂質異常症治療劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee